Accueil   Diary - News   All news Valneva : 2 new deals

Valneva : 2 new deals

Valneva Announces Two New Deals on its EB66® Vaccine Cell
Line Platform

Valneva, a leading pure play vaccines biotech company, announced today that it has signed a new research license agreement with Merial and a commercial license agreement with an undisclosed European company to develop veterinary vaccines using Valneva’s EB66® vaccine cell line platform.

Read the press release